United States: FDA Advances LDT Dialogue With New Discussion Paper Containing Updated CMS/FDA Oversight Proposal

Last Updated: January 19 2017
Article by Kevin M. Madagan

On January 13, 2017, the Food and Drug Administration (FDA) released a discussion paper concerning an updated proposed framework for oversight of laboratory developed tests (LDTs). According to FDA, the updated proposal is the result of ongoing engagement with industry stakeholders. Under the proposal, the FDA generally stands by its position that a complementary risk-based oversight framework that involves both the FDA and the CMS Clinical Laboratory Improvements Amendments (CLIA) program is the preferable alternative to a CMS-only framework. However, the updated proposal generally scales back FDA's involvement in the framework and emphasizes the need for regulatory flexibility.

FDA's new discussion paper does not represent the formal position of FDA, nor is it enforceable. The paper is meant merely to "advance the public discussion" by providing "a possible approach to spur further dialogue."

Do not let this disclaimer (or the upcoming change in White House administration) dissuade you from reading the new paper. Change is coming for LDTs and diagnostics generally, regardless of who is in the White House. If your business relates in any way to LDTs and diagnostic tests currently regulated by FDA, then we suggest taking the time to read FDA's updated proposed oversight framework and considering how this could impact your business operations and projections over the next decade and beyond.

Focused Oversight

FDA now proposes a prospective oversight framework that focuses on new and significantly modified high- and moderate-risk LDTs. Under this framework, previously marketed LDTs would be grandfathered – that is, they would not be expected to comply with most, if not all, of the FDA regulatory requirements. Additionally, certain new and significantly modified LDTs would likewise be exempt from a range of FDA requirements. Specifically, these exempt LDTs would be: (1) low-risk LDTs, (2) LDTs for rare diseases, (3) traditional LDTs, (4) LDTs intended solely for public health surveillance, (5) certain LDTs used in CLIA-certified, high-complexity histocompatibility labs, and (6) LDTs intended solely for forensic use.

However, the FDA would retain the ability to enforce regulatory requirements for any LDT, including these generally exempted LDTs, if the agency identifies any of the following issues: (1) the LDT is not analytically or clinically valid, (2) the LDT manufacturer has been engaged in deceptive promotion, or (3) there is reasonable probability that the LDT will cause death or serious adverse health consequences.

Risk-Based, Phased-In Oversight

FDA's new discussion paper contemplates a shorter phase-in period than was proposed in the Agency's 2014 draft guidance; specifically, premarket review for new and significantly modified LDTS could be phased in over four years, rather than nine. This four-year phase-in would first focus on the highest-risk tests and move on to other less-risky tests by year four. The FDA would allow tests introduced between the effective date of the finalized framework and the phase-in date for said date to continue to be offered for clinical use during the premarket review period, in order to ensure that patient access is not disrupted. Additionally, FDA's new discussion paper contemplates a more broadly defined "unmet need" category that would allow greater flexibility for LDTs that address unmet need than was originally proposed in 2014.

Evidence Standards

FDA intends for the premarket review process, where required, to be complementary to, and not duplicative of, CMS' postmarket oversight. Under this approach, FDA contemplates engaging with industry to determine how existing review programs could be leveraged to reduce the burden of conducting premarket review.

Third-Party Review

FDA contemplates expanding its third-party premarket review program to include eligible LDTs. For example, FDA is exploring whether to accept New York Department of Health's Clinical Laboratory Evaluation Program determinations in lieu of the FDA's own determinations.

Clinical Collaboratives

The FDA contemplates expanding its collaboration with industry to develop measurement and review standards, and to promote efficiency with regard to any future oversight framework.


The FDA would make evidence of analytical and clinical validity for all LDTs available to the public to ensure transparency.


The FDA emphasizes the need for regulatory flexibility to enable laboratories to make modifications to LDTs without undue burden, while still providing assurances to users that these modifications do not affect validity. To this end, the FDA would encourage laboratories to submit prospective change protocols in their premarket submissions. Subsequent modifications made in accordance with this change policy could then be made without the need for a new submission.

Leveraging CMS/CLIA: Quality System Requirements for LDTs

With regard to current quality system (QS) requirements, the FDA now proposes leveraging certification to CLIA requirements, even though these requirements are not fully consistent with the FDA QS requirements. For LDTs made in a CLIA-certified laboratory, the FDA would narrowly focus its assessment on only three FDA QS requirements that address aspects of test development not covered by CLIA: (1) design controls, (2) acceptance activities, and (3) procedures for implementing corrective and preventive actions. To this end, the FDA would also expand its third-party inspection program for LDTs so that many of these QS inspections could be conducted by FDA-accredited third parties.

Postmarket Surveillance

The updated proposed framework would initially require laboratories to report serious adverse events to the FDA with certain exceptions. The FDA indicates that, in the future, it may be able to decrease or discontinue such reporting as monitoring efforts mature.

With the release of this new discussion paper, FDA has signaled its intent to continue to drive the LDT discussion through transparency and additional engagement with all interested parties. Although FDA has not requested written comments to the new discussion guide, that fact should not stop you from informing the Agency about the feasibility of this new (or updated) proposed framework for regulating LDTs.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.